Selected Publications

Talleur AC, Fabrizio VA, Aplenc R, Grupp SA, Mackall C, Majzner R, Nguyen R, Rouce R, Moskop A, McNerney KO: INSPIRED Symposium Part 5: Expanding the Use of CAR T Cells in Children and Young Adults. Transplant Cell Ther 30(6): 565-579, June 2024 Notes: doi: 10.1016/j.jtct.2024.04.004.

Tarlock K, Gerbing RB, Ries RE, Smith JL, Leonti AR, Huang BJ, Kirkey DC, Robinson L, Peplinski JH, Lange B, Cooper TM, Gamis AS, Kolb EA, Aplenc R, Pollard JA, Meshinchi S: Prognostic Impact of Co-occurring Mutations in FLT3-ITD Pediatric Acute Myeloid Leukemia. Blood Adv 8(9): 2094-2103, May 2024 Notes: doi: 10.1182/bloodadvances.2023011980.

Myers RM, Devine KJ, Li Y, Lawrence S, Barz Leahy A, Liu H, Vernau L, Callahan C, Baniewicz D, Kadauke S, McGuire R, Wertheim G, Kulikovskaya I, Gonzales V, Fraietta JA, DiNofia A, Hunger SP, Rheingold SR, Aplenc R, June CH, Grupp SA, Wray L, Maude SL: Reinfusion of CD19 CAR T Cells for Relapse Prevention and Treatment in Children with Acute Lymphoblastic Leukemia. Blood Adv 8(9): 2182-2192, May 2024 Notes: doi: 10.1182/bloodadvances.2024012885.

Ruiz J, Kelly RK, Aplenc R, Laetsch TW, Seif AE: Absolute Neutrophil Count Clinical Trial Eligibility Criteria for Pediatric Oncology Phase I and Phase I/II Trials by Sponsorship. Pediatr Blood Cancer 71(5): e30925, May 2024 Notes: doi: 10.1002/pbc.30925.

van Dijk AD, Hoff FW, Qiu Y, Hubner SE, Go RL, Ruvolo VR, Leonti AR, Gerbing RB, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, de Bont ESJM, Horton TM, Kornblau SM: Chromatin Profiles Are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 Trial. Cancers 16(8): 1448, Apr 2024 Notes: doi: 10.3390/cancers16081448.

Abla O, Ries RE, Triche Jr TJ, Gerbing RB, Hirsch B, Raimondi S, Cooper TM, Farrar JE, Buteyn N, Harmon LM, Wen H, Deshpande AJ, Kolb EA, Gamis AS, Aplenc R, Alonzo T, Meshinchi S: Structural variants involving MLLT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemia. Blood Adv 8(8): 2005-2017, Apr 2024 Notes: doi: 10.1182/bloodadvances.2023010805.

Van Weelderen RE, Harrison CJ, Klein K, Jiang Y, Abrahamsson J, Alonzo T, Aplenc R, Arad-Cohen N, Bart-Delabesse E, Buldini B, De Moerloose B, Dworzak MN, Elitzur S, Fernandez Navarro JM, Gamis AS, Gerbing RB, Goemans BF, De Groot-Kruseman HA, Guest EM, Ha SY, Hasle H, Kelaidi C, Lapillone H, Leverger G, Locatelli F, Miyamura T, Noren-Nystrom U, Polychronopoulou S, Rasche M, Rubnitz JE, Stary J, Tierens A, Tomizawa D, Zwaan MC, Kaspers GJL: Optimized Cytogenetic Risk-Group Stratification of KMT2A-Rearranged Pediatric Acute Myeloid Leukemia. Blood Adv Apr 2024 Notes: doi: 10.1182/bloodadvances.2023011771.

Renaud J, Goemans BF, Locatelli F, Pigazzi M, Redmond S, Kuehni CE, Destaillats A, Alonzo TA, Gerbing RB, Gamis A, Aplenc R, Renella R, Cooper T, Ceppi F: Characteristics and treatment of acute myeloid neoplasms with cutaneous involvement in infants up to 6 months of age: A retrospective study. Pediatr Blood Cancer 71(7): e31006, Apr 2024 Notes: doi: 10.1002/pbc.31006.

Newman H, Li Y, Huang YV, Elgarten CW, Myers RM, Ruiz J, Zheng DJ, Barz Leahy A, Aftandilian C, Arnold SD, Bona K, Gramatges MM, Heneghan MB, Maloney KW, Modi AJ, Mody RJ, Morgan E, Rubnitz J, Winick N, Wilkes JJ, Seif AE, Fisher BT, Aplenc R, Getz KD: Household income and health-related quality of life in children receiving treatment for acute myeloid leukemia: Potential impact of selection bias in health equity research. Cancer Med 13(7): e6966, Apr 2024 Notes: doi: 10.1002/cam4.6966.

Cao L, Huang Y, Getz KD, Seif AE, Ruiz J, Miller TP, Fisher BT, Aplenc R, Li Y: Applying machine learning to identify pediatric patients with newly diagnosed acute lymphoblastic leukemia using administrative data. Pediatr Blood Cancer 71(3): e30858, Mar 2024 Notes: doi: 10.1002/pbc.30858.